T2624 |
OSI-930
|
728033-96-3
|
99.76%
|
|
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
|
T8721L |
I-37 free base( 2359690-13-2(free base))
|
T8721L
|
99.75%
|
|
I-37 free base is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
|
T6487 |
Encorafenib
|
1269440-17-6
|
99.74%
|
|
Encorafenib (LGX818) is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
|
T13037 |
Sulindac sulfide
|
49627-27-2
|
99.68%
|
|
Sulindac sulfide (cis-Sulindac sulfide) is a non-steroidal anti-inflammatory compound that has a high affinity for COX-1 and acts as an inhibitor in Ras activati...
|
T8006 |
Oncrasin-1
|
75629-57-1
|
99.68%
|
|
Oncrasin 1 is a potent inhibitor of anticancer that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations
|
T4133 |
CCT196969
|
1163719-56-9
|
99.65%
|
|
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.
|
T6277 |
Doramapimod
|
285983-48-4
|
99.65%
|
|
Doramapimod (BIRB 796) is a highly potent inhibitor of p38 MAPK (Kd: 0.1 nM), but weakly inhibits c-RAF, Fyn, Lck, ERK-1, SYK, IKK2, and ZAP-70.
|
T2382 |
Vemurafenib
|
918504-65-1
|
99.65%
|
|
Vemurafenib (RG7204) (PLX4032) is a novel and potent B-Raf (V600E) inhibitor (IC50: 31 nM).
|
T8746L |
I-49 free base
|
T8746L
|
99.64%
|
|
I-49 free base (Pyrido[4,3-d]pyrimidin-7(6H)-one, 2-methyl-4-[[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]amino]-6-(tetrahydro-2H-pyran-4-yl)-) is a novel ...
|
T0093L |
Sorafenib
|
284461-73-0
|
99.61%
|
|
Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/...
|
T2293 |
SGX-523
|
1022150-57-7
|
99.6%
|
|
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
|
T2473 |
PLX-4720
|
918505-84-7
|
99.5%
|
|
PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations).
|
T1792L |
Regorafenib monohydrate
|
1019206-88-2
|
99.47%
|
|
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR...
|
T19802 |
B-Raf IN 11
|
918504-27-5
|
99.46%
|
|
B-Raf IN 11 is a novel selective inhibitor. The DFG-in conformation of the B-Raf kinase V600E mutant is superior to the DFG-out conformation in colorectal cancer...
|
T8474 |
Dabrafenib Mesylate
|
1195768-06-9
|
99.45%
|
|
Dabrafenib Mesylate (GSK2118436 Mesylate) is a B-Raf inhibitor(IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively).
|
T6555 |
K-Ras(G12C) inhibitor 12
|
1469337-95-8
|
99.44%
|
|
K-Ras(G12C) inhibitor 12 is an allosteric inhibitor of oncogenic K-Ras(G12C).
|
T3711 |
RAF709
|
1628838-42-5
|
99.43%
|
|
RAF709 is a novel Raf kinase inhibitor with IC50s of 0.5 and 1.8 nM for c-Raf and b-Raf, respectively.
|
T8745 |
PROTAC BRAF-V600E degrader-1
|
2417296-84-3
|
99.43%
|
|
PROTAC BRAF-V600E degrader-1 (Compound 23) selectively induces degradation of BRAF-V600E but not wildtype BRAF.
|
T9693 |
TBAP-001
|
1777832-90-2
|
99.3%
|
|
TBAP-001 is a RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay and an IC50 of 18 nM in Cell-Based Phosho-ERK Assay.
|
T63644 |
Exarafenib
|
2639957-39-2
|
99.26%
|
|
Exarafenib (RAF/KIN_2787) is a potent and orally available pan-RAF inhibitor.Exarafenib has antitumor activity and acts by inhibiting downstream MAPK pathway sig...
|